Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 1;27(19):5280–5288. doi: 10.1158/1078-0432.CCR-21-0793

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.

PMC Copyright notice

Figure 1. Best percentage change from baseline in target lesion size (RECIST, version 1.1, by central review) in patients in PEM200+IPI50 (pembrolizumab 200 mg Q3W + ipilimumab 50 mg Q6W; A) and PEM200+IPI100 (pembrolizumab 200 mg Q3W + ipilimumab 100 mg Q12W; B). Abbreviations: Q3W, every 3 weeks; Q6W, every 6 weeks; Q12W, every 12 weeks. — Best percentage change from baseline in target lesion size (RECIST, version 1.1, by central review) in patients in PEM200+IPI50 (pembrolizumab 200 mg Q3W + ipilimumab 50 mg Q6W; A) and PEM200+IPI100 (pembrolizumab 200 mg Q3W + ipilimumab 100 mg Q12W; B). Abbreviations: Q3W, every 3 weeks; Q6W, every 6 weeks; Q12W, every 12 weeks.